Takahiro Shimoyama ¹, Takayuki Yamamoto ², Satoru Umegae ¹, Koichi Matsumoto ¹ , BMC Gastroenterol. 2018 Aug 1;18(1):120.

Our findings indicate that FC is a relevant biomarker, which is convenient to measure for assessing endoscopic activity and predicting relapse in patients who achieve remission following a course of GMA therapy.

https://pubmed.ncbi.nlm.nih.gov/30068300/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090982/pdf/12876_2018_Article_853.pdf

Selective myeloid leucocyte depletion was effective for remission induction and improving patients’ quality of life. Baseline demographics such as disease activity level, duration and corticosteroid dependency appear to predict response to GMA. Additionally, patients with a first UC episode who were drug naive responded well to GMA and achieved a favorable long-term disease course by avoiding pharmacologics from an early stage of their inflammatory bowel disease. These findings should help to end unnecessary use of medical resources by targeting GMA to patients who may respond well.

Yoko Yokoyama ¹, Kenji Watanabe ², Hiroaki Ito ³, Masakazu Nishishita ⁴, Koji Sawada ⁵, Yusuke Okuyama ⁶, Kazuichi Okazaki ⁷, Hisao Fujii ⁸, Hiroshi Nakase ⁹, Tsutomu Masuda ¹⁰, Ken Fukunaga ¹¹, Akira Andoh ¹², Shiro Nakamura ¹³ ,

Cytotherapy 2015 May;17(5):680-8. 

https://pubmed.ncbi.nlm.nih.gov/25804800/